Clinical Outcomes Associated With Long‐Acting Beta Agonist Escalation in Preschool Children With Severe Asthma: A Retrospective Hospital Based Clinic Cohort Study
Pediatric Pulmonology · 2026-05 · 61 (5)
DOI: 10.1002/ppul.71654 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Pediatric Pulmonology, online erschienen am 06.05.2026. Verfasst von Adi Meridor Eizner und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonology Unit, Wolfson Medical Center, Holon, Israel. Hauptthemen laut MEDLINE: Asthma, Adrenal Cortex Hormones, Adrenergic beta-Agonists, Anti-Asthmatic Agents. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
We define adherent, difficult‐to‐treat asthma as ‘true severe asthma.' In preschool children, evidence for add‐on long‐acting beta‐agonists (LABA) to inhaled corticosteroids (ICS) in those with persistent uncontrolled disease despite high‐dose ICS remains limited. We evaluated clinical outcomes of ICS–LABA therapy in this population.
Methods
This retrospective observational study (2021–2024) included children aged 6–72 months with severe, uncontrolled asthma despite medium‐ to high‐dose ICS and verified adherence, who were initiated on LABA therapy. Primary outcomes were severe exacerbations (systemic corticosteroid use, hospitalizations, and uncontrolled symptoms). Secondary outcomes included PICU admissions and spontaneously reported adverse events. Outcomes 6 months before and after LABA initiation were compared using generalized estimating equations (GEE), adjusting for seasonality, age, sex, and atopy.
Results
Fifty‐three children were included (mean age 38.8 ± 17.6 months, 41.5% male, atopy 49.1%). LABA initiation was associated with a substantial reduction in clinical burden: hospitalizations declined from 41.5% to 3.8% ( p < 0.001), systemic corticosteroid use from 86.8% to 52.8% ( p < 0.001), and daily symptoms from 86.8% to 37.7% ( p < 0.001). PICU admissions decreased from 9.4% to 0%. These associations remained significant after adjustment for covariates ( p < 0.001). No adverse events were spontaneously reported by patients or caregivers during the follow‐up period; however, systematic adverse event surveillance was not conducted.
Conclusion
In adherent preschool children with true severe asthma, LABA initiation was associated with observed improvements in clinical outcomes. Still, prospective controlled studies with systematic safety surveillance are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatric Pulmonology Unit, Wolfson Medical Center, Holon, Israel.
- Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.
- Allergy and Immunology, Wolfson Medical Center, Holon, Israel.
ORCID-Profile: Adi Meridor Eizner
Zitieren
APA
Eizner, A. M., Mandelberg, A., Ovadia, A., & Domany, K. A. (2026). Clinical Outcomes Associated With Long‐Acting Beta Agonist Escalation in Preschool Children With Severe Asthma: A Retrospective Hospital Based Clinic Cohort Study. Pediatric Pulmonology, 61(5). https://doi.org/10.1002/ppul.71654
Vancouver
Eizner AM, Mandelberg A, Ovadia A, Domany KA. Clinical Outcomes Associated With Long‐Acting Beta Agonist Escalation in Preschool Children With Severe Asthma: A Retrospective Hospital Based Clinic Cohort Study. Pediatric Pulmonology. 2026;61(5). doi:10.1002/ppul.71654
BibTeX
@article{Eizner2026,
author = {Eizner, Adi Meridor and Mandelberg, Avigdor and Ovadia, Adi and Domany, Keren Armoni},
title = {Clinical Outcomes Associated With Long‐Acting Beta Agonist Escalation in Preschool Children With Severe Asthma: A Retrospective Hospital Based Clinic Cohort Study},
journal = {Pediatric Pulmonology},
year = {2026},
volume = {61},
number = {5},
doi = {10.1002/ppul.71654}
}
EUVIMED